ArticleTranslational cancer research2025
A deep learning-based prognostic prediction model for distal cholangiocarcinoma incorporating the metabolism-inflammation marker monocyte-to-high-density lipoprotein cholesterol ratio.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory responses and lipid metabolism play a pivotal role in tumor initiation and progression, significantly impacting the prognosis of patients with malignant tumors. This study aims to investigate the prognostic relevance of the monocyte-to-high-density lipoprotein cholesterol ratio (MHR)-a novel inflammation-metabolism biomarker-in patients with distal cholangiocarcinoma (dCCA), leveraging deep learning-based analytical approaches. Methods: Clinicopathological records of dCCA patients managed at The First Affiliated Hospital of Bengbu Medical University (Bengbu, China) between January 2011 and July 2023 were retrospectively reviewed. Receiver operating characteristic (ROC) analysis was performed and the area under the curve (AUC) used to quantify the ability of MHR to predict outcomes. Associations were evaluated using Cox proportional hazards regression in both univariable and multivariable forms. Predictors that remained in the multivariable model were compared with the highest-importance features from the random forest ranking; the intersecting variables were incorporated to construct a survival-prediction nomogram. Results: One hundred and eighty-eight patients with dCCA following radical pancreaticoduodenectomy (PD) were enrolled. The area under AUC for MHR in predicting 1-year postoperative survival was 0.651 [95% confidence interval (CI): 0.5538-0.7485], with an optimal cutoff value of 0.74. Patients were divided into a high MHR group (MHR >0.74, n=82) and a low MHR group (MHR ≤0.74, n=106) based on this cutoff value. The median disease-free survival (DFS) time were 42 months and 18 months, respectively (P=0.002) whereas median overall survival (OS) times for the low and high MHR groups were 36 months and 17 months, respectively (P<0.001). Multivariate analyses combined with random forest analysis and least absolute shrinkage and selection operator (LASSO) regression identified that preoperative MHR, carbohydrate antigen 19-9 (CA19-9), lymph node metastases, portal system invasion and tumor differentiation were independent predictors of postoperative mortality. Conclusions: By combining a readout of systemic inflammation with HDL-related lipid status, MHR emerges as an informative prognostic index in dCCA. In parallel, CA19-9 concentration, nodal involvement, portal system invasion, and histologic differentiation are each independently associated with survival. Integrating these variables within our deep-learning-based prognostic model enables earlier risk triage and more targeted postoperative management, with potential to improve clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.